Now more than ever, it is undeniable how integral science and research have become to public health. Nationwide, doctors, scientists and experts are working around the clock to find the most up-to-date and reliable information to prevent and stop the spread of Covid-19.
Here are five must-know women who are shattering ceilings, making groundbreaking discoveries, and spreading public awareness during the global pandemic.
Joy Buolamwini is the founder of the Algorithmic Justice League (AJL), a computer scientist and an expert in artificial intelligence bias. Four years ago, when Buolamwini was a graduate student at MIT’s Media Lab, she began looking into the racial and gender disparities in commercially-available facial recognition technologies. Her research culminated in two groundbreaking, peer-reviewed studies, published in 2018 and 2019, that revealed
In the world of synthetic biology, the development of foundational components like logic gates and genetic clocks has enabled the design of circuits with increasing complexity, including the ability to solve math problems, build autonomous robots, and play interactive games. A team of researchers at the Georgia Institute of Technology is now using what they’ve learned about bio-circuits to lay the groundwork for the future of programmable medicine.
Looking like any other small vial of clear liquid, these programmable drugs would communicate directly with our biological systems, dynamically responding to the information flowing through our bodies to automatically deliver proper doses where and when they are needed. These future medicines might even live inside us throughout our lives, fighting infection, detecting cancer and other diseases, essentially becoming a therapeutic biological extension of ourselves.
Over the past decade, we witnessed unprecedented advances in the field of biogerontology, and the massive convergence of biotechnology, information technology, AI, and medicine. And now we are witnessing the birth of a new field of longevity medicine, which integrates the latest advances in many of these fields of science and technology. My definition longevity medicine is advanced personalized preventative medicine powered by deep biomarkers of aging and longevity.
And, like in the field of AI for drug discovery, women are at the forefront of this revolution and there were precedents when we had to look for a male physician to make a conference panel more diverse.
One of the physician-scientists who stands out in this area is Dr. Evelyne Yehudit Bischof. I first got a note with a request for more information on one of
The “Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape – Analysis and Forecast, 2020-2030” report has been added to ResearchAndMarkets.com’s offering.
Global Precision Medicine Market to Reach $278.61 Billion by 2030
Precision medicine refers to the medicine developed as per an individual’s genetic profile. It provides guidance regarding the prevention, diagnosis, and treatment of diseases. The segmentation of the population is done depending on the genome structure of the individuals and their compatibility with a specific drug molecule.
In the precision medicine market, the application of molecular biology is to study the cause of a patient’s disease at the molecular level, so that target-based therapies or individualized therapies can be applied to cure the patient’s health-related problems.
This industry is gaining traction due to the increasing awareness about healthcare among individuals, integration of smart devices such as smartphones and tablets into healthcare,
Wednesday, September 30, 2020 – Insilico Medicine, a global leader in artificial intelligence for drug discovery and development, will present its latest results in modern and next-generation AI for drug discovery and productive longevity at the Live Leveraging Intelligent Tech for Drug Development Forum on September 30, 2020.
AI, automation and data integration are condensing the timeline from discovery to development and solving biological problems. On September 30th, leaders from biotech and pharma will discuss specific examples of how these technological advancements are reshaping the drug development landscape.
While technology continues to revolutionize biotech, pharmaceutical companies are investing heavily in modernizing internally to embrace and embed these innovations throughout their organizational structure and culture. On the clinical trial front, not only are sponsors pressed to have remote and decentralized designs for their trial models due to the ongoing
Helium balloons are a quintessential party favor, a fixture of any birthday, wedding or anniversary party. But few consumers seem to know that helium is a limited resource — and one which physics experiments and medical imaging tools rely on to work. Worse, once a helium balloon pops, that gas is lost forever — it floats upwards and escapes into space, never to be seen on Earth again.
Now, with the specter of a recent helium shortage still looming, consumers are being asked to ration their helium in order to save science and medicine. The idea that party supply companies and consumers can’t give up helium balloons in order to save these more worthy enterprises might seem a tad selfish; but this is how the market thinks. Yet a few inventors around the country have a brilliant compromise: what if we could make a “balloon” that needed no helium gas
“It is more important to know what kind of patient the disease has than to know what kind of disease the patient has.”
Although Hippocrates made this keen observation more than 2,400 years ago, physicians did not have the tools to decipher the biological and environmental factors influencing an individual’s health and well-being until recently.
Since the human genome was finally mapped in 2003, scientists have made tremendous progress in advancing personalized medicine. By tailoring health care to an individual’s biological characteristics, circumstances, and values, personalized medicine can bring unprecedented benefits to patients with rare genetic disorders, cancer, and other diseases.
The widely variable effects of the novel coronavirus serve as a painful reminder of the importance of understanding how and why people respond differently to the same disease.
But two recent moves by the Trump administration threaten to turn back the clock on biomedical progress in personalized
Singapore, 22 September 2020 – Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRF’s initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.
SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.
“Singapore’s well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing